A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Poly I: Poly C12U (Ampligen®) 400 MG IV Twice Weekly Versus Placebo in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME).
Design: Mission Data?
Subjects who meet the following criteria may be eligible for study participation.
The study is open to enrollment.
Eleven centers in the US are currently participating in this study. Cities with participating centers are:
Fountain Valley, CA
San Diego, CA
New Brunswick, NJ
New Providence, NJ
Incline Village, NV
Glenn Mills, PA
Please contact Hemispherx Biopharma for additional information regarding trial locations and site contacts: